IQVIA Holdings Inc (IQV) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
IQVIA Holdings Inc stock (IQV) is currently trading at $165.64. IQVIA Holdings Inc PE ratio is 21.18. IQVIA Holdings Inc PS ratio (Price-to-Sales) is 1.72. Analyst consensus price target for IQV is $236.19. WallStSmart rates IQV as Moderate Buy.
- IQV PE ratio analysis and historical PE chart
- IQV PS ratio (Price-to-Sales) history and trend
- IQV intrinsic value — DCF, Graham Number, EPV models
- IQV stock price prediction 2025 2026 2027 2028 2029 2030
- IQV fair value vs current price
- IQV insider transactions and insider buying
- Is IQV undervalued or overvalued?
- IQVIA Holdings Inc financial analysis — revenue, earnings, cash flow
- IQV Piotroski F-Score and Altman Z-Score
- IQV analyst price target and Smart Rating
IQVIA Holdings Inc
📊 No data available
Try selecting a different time range
IQV Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · IQVIA Holdings Inc (IQV)
IQV trades at a significant discount to its Graham intrinsic value of $348.46, offering a 49% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
IQVIA Holdings Inc (IQV) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, return on equity. Overall metrics suggest strong investment potential with favorable risk/reward.
IQVIA Holdings Inc (IQV) Key Strengths (6)
Growing significantly faster than its price suggests
103.32% of shares held by major funds and institutions
Large-cap company with substantial market presence
Every $100 of equity generates $21 in profit
Paying $1.72 for every $1 of annual revenue
Strong earnings growth at 23.60% per year
Supporting Valuation Data
IQVIA Holdings Inc (IQV) Areas to Watch (4)
Premium pricing at 4.3x book value
Thin profit margins with limited profitability
Decent operational efficiency, solid but not exceptional
Solid revenue growth at 10.30% per year
IQVIA Holdings Inc (IQV) Detailed Analysis Report
Overall Assessment
This company scores 72/100 in our Smart Analysis, earning a B grade. Out of 10 metrics analyzed, 6 register as strengths (avg 9.0/10) while 4 fall into concern territory (avg 5.0/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on PEG Ratio, Institutional Own., Market Cap. Valuation metrics including PEG Ratio (0.97), Price/Sales (1.72) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 21.40%. Growth metrics are encouraging with EPS Growth at 23.60%.
The Bear Case
The primary concerns are Price/Book, Profit Margin, Operating Margin. Some valuation metrics including Price/Book (4.29) suggest expensive pricing. Growth concerns include Revenue Growth at 10.30%, which may limit upside. Profitability pressure is visible in Operating Margin at 15.20%, Profit Margin at 8.34%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 21.40% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 10.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of PEG Ratio and Institutional Own. makes a compelling case at current levels. The key risk is Price/Book, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IQV Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IQV's Price-to-Sales ratio of 1.72x trades 25% below its historical average of 2.31x (29th percentile). The current valuation is 57% below its historical high of 3.98x set in Jun 2021, and 58% above its historical low of 1.09x in Aug 2013. Over the past 12 months, the PS ratio has compressed from ~2.1x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for IQVIA Holdings Inc (IQV) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
IQVIA Holdings Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 16.3B with 10% growth year-over-year. Profit margins are thin at 8.3%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 2140.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 561M in free cash flow and 735M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can IQVIA Holdings Inc push profit margins above 15% as the business scales?
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact IQVIA Holdings Inc.
Bottom Line
IQVIA Holdings Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About IQVIA Holdings Inc(IQV)
NYSE
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.